AstraZeneca Reports Strong Q2 Earnings Driven by Cancer Drug Sales
AstraZeneca (AZN) reported second-quarter earnings that exceeded Wall Street expectations, primarily due to strong sales of its cancer drugs. The company's core earnings per share reached $2.63, surpassing the consensus estimate by $1.36. Total revenue grew by 5% year over year at constant exchange rates. The performance was fueled by demand for AstraZeneca’s blockbuster oncology treatments, which continue to drive growth and profitability. The results highlight the company's strong position in key therapeutic areas despite broader market challenges.
Tickers: $AZN